Barr Laboratories has received final approval from the U.S. Food and Drug Administration (FDA) for its application to manufacture and market a generic version of Pfizer’s Xanax XR (alprazolam extended-release) tablets, 0.5 mg, 1 mg, 2 mg, and 3 mg. The company intends to launch its product immediately.

Generic Xanax XR Tablets are indicated for the treatment of panic disorder, with or without agoraphobia.

Random Posts:

• Early Breast Cancer May Benefit from Letrozole
• Raltegravir (Isentress) For HIV Infection
• Warning for Colorectal Drug
• Monitoring Blood Glucose In Stroke Patients
• Atypical Antipsychotic Agents For Alzheimer’s Disease: Risks May Outweigh Benefits